13F Pro quality score
Rank #1,997 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from biote Corp.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $192.2M | $27.0M | 18.5% |
| FY 2024 | 10-K | $197.2M | $3.2M | 16.0% |
| FY 2023 | 10-K | $185.4M | $3.3M | 15.5% |
| FY 2022 | 10-K | $165.0M | $-969.0K | -36.8% |
| FY 2021 | 10-K | $139.4M | $11.1M | 24.8% |
Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
biote Corp. (BTMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BTMD at 42.7/100 on a composite quality score built from its SEC filings, placing it at rank #1,997 of 2,925 stocks — the bottom half of the AI-ranked universe. BTMD scores in the top quartile across earnings quality (93.6). Areas of concern include institutional flow (2.4) and revenue growth (22.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), biote Corp. reports quarterly revenue of $44.2M, net income of $-6.6M, an operating margin of -7.9%. Top institutional holders of BTMD by reported 13-F value include 325 CAPITAL, Bandera Partners, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BTMD trades on the Nasdaq exchange and files with the SEC under CIK 1819253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for biote Corp. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1819253 →